Effects of glucagon-like peptide-1 agents on left ventricular function: Systematic review and meta-analysis

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

(2013) B. Wang et al.   DIABETES OBESITY & METABOLISM

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials

(2013) M. Monami et al.   DIABETES OBESITY & METABOLISM

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metabolic Effects of Short-term GLP-1 Treatment in Insulin Resistant Heart Failure Patients

(2012) R. Nielsen et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Exenatide Alters Myocardial Glucose Transport and Uptake Depending on Insulin Resistance and Increases Myocardial Blood Flow in Patients with Type 2 Diabetes

(2012) M. Gejl et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure

(2011) Joanna Hlebowicz et al.   Cardiovascular Ultrasound

A Pilot Study to Assess Whether Glucagon-Like Peptide-1 Protects the Heart From Ischemic Dysfunction and Attenuates Stunning After Coronary Balloon Occlusion in Humans

(2011) Philip A. Read et al.   Circulation-Cardiovascular Interventions

Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials

(2011) Y. Wang et al.   DIABETES OBESITY & METABOLISM

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

(2011) Jacob Lønborg et al.   EUROPEAN HEART JOURNAL

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

(2011) Philip A Read et al.   HEART

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

(2010) Mads Halbirk et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

(2010) Anne Gill et al.   Cardiovascular Diabetology

DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease

(2010) Philip A. Read et al.   Circulation-Cardiovascular Imaging

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database

(2010) J. H. Best et al.   DIABETES CARE

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans

(2008) Adil E. Bharucha et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION